ПРОИЗВОДНОЕ ПЕПТИДА, СПОСОБ ЛЕЧЕНИЯ РАКА У ПАЦИЕНТА

Производное пептида, содержащее остаток соматостатина, или бомбезина, или их производного, фрагмента или аналога, и заместитель формулы I, II или III (значения радикалов см. в п.1 формулы изобретения) имеет более высокую и продленную биологическую активность по сравнению с немодифицированным соматостатином. 2 с. и 15 з.п. ф-лы, 4 табл., 1 ил.

НОВЫЕ КЕТОАМИДЫ С ЦИКЛИЧЕСКИМ P4S, ДЕЙСТВУЮЩИЕ КАК ИНГИБИТОРЫ СЕРИНОВОЙ ПРОТЕАЗЫ NS3 ИРУСА ГЕПАТИТА С

... 1. Соединение или энантиомеры, стереоизомеры, ротамеры, таутомеры и рацематы указанного соединения или фармацевтически приемлемая соль, сольват или сложный эфир указанного соединения, причем указанное соединение имеет общую структуру, представленную формулой Iгде Rпредставляет собой Н, OR, NRRили CHRR, где R, Rи Rмогут быть одинаковыми или различными, причем каждый из них независимо выбран из группы, состоящей из Н, алкил-, алкенил-, алкинил-, арил-, гетероалкил-, гетероарил-, циклоалкил-, гетероциклил-, арилалкил- и гетероарилалкила;А и М могут быть одинаковыми или различными, причем каждый из них независимо выбран из R, OR, NHR, NRR', SR, SOR и галогена; или А и М связаны друг с другом (другими словами, вместе взятые A-E-L-M) таким образом, что фрагментуказанный выше в формуле I, образует либо трех-, четырех-, шести-, семи- или восьмичленный циклоалкил, либо четырех-восьмичленный гетероциклил, либо шести-десятичленный арил, либо пяти-десятичленный гетероарил;Е представляет собой С(Н) ...

НОВЫЕ СОЕДИНЕНИЯ, ДЕЙСТВУЮЩИЕ КАК ИНГИБИТОРЫ СЕРИНОВОЙ ПРОТЕАЗЫ NS3 ВИРУСА ГЕПАТИТА С

... 1. Соединение или энантиомеры, стереоизомеры, ротамеры, таутомеры или рацематы указанного соединения или фармацевтически приемлемая соль, сольват или сложный эфир указанного соединения, причем указанное соединение имеет общую структуру, представленную формулой Iформула Iгде Rпредставляет собой Н, OR, NRRили CHRR, где R, Rи Rмогут быть одинаковыми или различными, причем каждый из них независимо выбран из группы, состоящей из Н, алкил-, алкенил-, алкинил-, арил-, гетероалкил-, гетероарил-, циклоалкил-, гетероцикпил-, арилалкил- и гетероарилалкил;А и М могут быть одинаковыми или различными, причем каждый из них независимо выбран из R, OR, NHR, NRR', SR, SOR и галогена; или А и М связаны друг с другом таким образом, что радикал,приведенный выше в формуле I, образует либо трех-, четырех-, шести-, семи- или восьмичленный циклоалкил, либо четырех-восьмичленный гетероциклил, либо шести-десятичленный арил, либо пяти-десятичленный гетероарил;Е представляет собой С(Н) или C(R);L представляет собой ...

ПРИМЕНЕНИЕ БИОЛОГИЧЕСКИ АКТИВНЫХ УРЕИДОПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ ИНДУЦИРУЕМЫХ ЛЕНТИВИРУСАМИ ЗАБОЛЕВАНИЙ, ПРОДУКТЫ, СОДЕРЖАЩИЕ УРЕИДОПРОИЗВОДНЫЕ

Для приготовления лекарственного средства, предназначенного для лечения инфекции лентивируса, предложено соединение формулы, приведенной в описании, или его фармацевтически приемлемая соль.

Способ получения индоксильных или тиоиндоксильных сложных эфиров аминокислот или пептидов

СПОСОБ ПОЛУЧЕНИЯ ИНДОКСИЛЬ НЫХ ИЛИ ТИОИНДОКСИЛЬНЫХ СЛОЖНЫХ ЭФИ РОВ АМИНОКИСЛОТ или ПЕПТИДОВ общей формулы I 0-А-В где . - одинаковые или различны и означают водород, гал ид, низпгую . алкильную, а коксильную, арильную, ар кильную, аралкоксильнуго, гидроксильную, карбоксил ную, карбокси (низший) ал ксильную, аралкоксикарбонильную , аралкоксикарбоНШ1 (низший) алкоксипьную , нитро- или низшую ациламиногруппу, или два соседних заместителя означают бензоаннелирован- ный остаток; X - сера или незамещенная иминогруппа или замещенная алкильным, аралкильньм , арильным или ацильным остатком, иминогруп- па; А - моноаминокарбоновая кислота или аланинсодержащий ди- или три-пептидный остаток; В - N-защитная группа в пептидной части (остатке), чающийся тем, что ие общей формулы И имеют указанные значения, ют взаимодействию с галоидани или смешанными ангидридами, вированными сложными эфирами бщей формулы III Н - О - А - В В имеют указанные значения.

Angiotensin-Converting-Enzyme-Hemmer

PEPTIDYL-N HOCH G -CARBOXY-ARGININ- ALDEHYDE, VERFAHREN ZUR HERSTELLUNG DERSELBEN UND DIESE ENTHALTENDE ARZNEIMITTEL

KASKADEN-POLYMER-KOMPLEXE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE MITTEL

PEPTID-DERIVATE DES 7-AMINO-4METHYLCUMARINS

PEPTIDES

Histidine peptides and process for producing them

The invention comprises N(Im)-carbobenzoxy histidine compounds of the formulae:- wherein Cbz represents carbobenzoxy (-CO.O.CH2Ph), X represents halogen (e.g. Cl, Br, I), P represents C1-8 alkoxy, substituted or unsubstituted phenyl (C1-8) alkoxy (e.g. -O-CH2Ph, -O-CH2-C6H4-NO2-p) or a radical -NH-Q11-CO-P1, wherein P1 represents C1-8 alkoxy or substituted or unsubstituted phenyl (C1-8) alkoxy, Q and Q11 represent residues derived from an amino acid or a peptide by loss of a terminal amino and a terminal carboxylic group, and R represents an amino protecting group (e.g. -CO.O.CH2Ph, -C(Ph)3, -SO2.C6H4.CH3-p, -CHO, -CO.O.C(CH3)3). In the above compounds any carboxyl and/or other functional groups in the residues Q and Q11 may be blocked by suitable protecting groups. Thus, the alcoholic radical in the tyrosine residue may be protected as benzyloxy (-O.CH2Ph); the thiol radical in the cysteine residue as benzylthio (-S.CH2Ph), the amino radical in the lysine and ornithine ...

The invention comprises compounds of the general formula H2N-R-CO-Y1 where R is an aminomethyl - methylene, aminoethyl-methylene, aminopropyl - methylene, aminobutyl - methylene or (3 - guanidino propyl)-methylene group and Y1 is a hydroxy or alkoxy group; one of the amino groups or the guanidino group being substituted by a saturated or unsaturated aliphatic long-chain acyl group containing at least ten carbon atoms and the other amino or guanidino group being protected with a removable protecting group. The compounds are prepared by acylating the corresponding N-protected amino acid or ester with an agent which introduces a saturated or unsaturated aliphatic long chain acyl group on to the unprotected amino group and, if desired esterifying any free acid or de-esterifying any ester obtained. Ne -Phthaloyl-L-lysine ethyl ester hydrochloride is prepared from the free acid by reaction with ethanol and hydrochloric acid.

Inhibitors of interleukin-1B converting enzyme.

Compounds that are inhibitors of interleuken-lB converting enzyme and are representing by the formula: The ICE inhibitors have specific structural and physicochemical features. The compounds and compositions thereof are suited for inhibiting ICE activity and may be used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases.

New peptides derivatives.

The invention relates to new competitive inhibitors of ...

Treatment of insulin resistance with growth hormone secretagogues.

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula i, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula i are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula i. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound ...

NEW PEPTIDES DERIVATIVES

Treatment of insulin resistance

Inhibitors of interleukin-1B converting enzyme

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Compounds of Formula (I), where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their sythesis.

Compounds of formula (I) where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. Theses compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Treatment of insulin resistance with growth hormone secretagogues

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Peptides that block human immunodeficiency virus i

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Treatment of insulin resistance

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

NEW PEPTIDES DERIVATIVES

Inhibitors of interleukin-1B converting enzyme

PROCEDURE FOR THE PRODUCTION OF NEW PEPTID DERIVATIVES

PROCEDURE FOR THE PRODUCTION OF NEW PEPTIDYL ARGININ ALDEHYDE DERIVATIVES AS WELL AS OF SALTS OF THESE CONNECTIONS

VERFAHREN ZUR HERSTELLUNG VON NEUEN PEPTID- DERIVATEN

VERFAHREN ZUR HERSTELLUNG NEUER PEPTIDDERIVATE

NEW KETOAMIDE WITH CYCLI P4 AS INHIBITORS of the NS3-SERINPROTEASE OF HEPATITIS C VIRUS

COMPOSITIONS AND PROCEDURES FOR A HEALTHY PREGNANCY

PROCEDURE FOR THE PRODUCTION OF NEW PEPTIDDERIVATE

PROCEDURE FOR THE PRODUCTION OF NEW PEPTIDDERIVATEN AND THEIR SALTS

N (N' (2-CHLORAETHYL) - N' NITROSO CARBAMOYL) OLIGOPEPTIDESTER AND - AMIDES AND PROCEDURES FOR YOUR PRODUCTION.

NEW PEPTIDASEN AND ISOMERASEN INHIBITORS.

AMINOSUBSTITUIERTE TETRALINE AND RELATED HOMOCYCLI CONNECTIONS.

CHROMOGENE CONNECTIONS, YOUR PRODUCTION AND USE AS ENZYME SUBSTRATES.

PEPTIDE WITH ENDOTHELIN ANTAGONISTIC ACTIVITY, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS

N-SUBSTITUTING HETERO-CYCLIC DERIVATIVES, PROCEDURES FOR THEIR PRODUCTION, THESE CONTAINING COMPOSITIONS

PROCEDURE FOR THE PRODUCTION OF HGRF (SOMATOCRININ) IN LIQUID PHASE AND PEPTIDEZWISCHENVERBINDUNGEN.

PEPTIDE WITH UBIQUITIN AEHNLICHER ACTIVITY, PROCEDURE FOR THEIR PRODUCTION, IT ABSTENTION THERAPEUTIC COMPOSITIONS AND YOUR APPLICATION.

DIAGNOSTIC MEANS FOR THE PROOF OF PROTEOLYTIC ENZYMES AS WELL AS CHROMOGENE FOR THIS SUITABLE INDOXYL AND/OR THIOINDOXYLESTER, PROCEDURE FOR THEIR PRODUCTION AS WELL AS THEIR USE FOR THE PRODUCTION OF DIAGNOSTIC MEANS.

PEPTID CONNECTIONS, THEIR PROCEDURES FOR THE PRODUCTION AND IT ABSTENTION PHARMACEUTICAL COMPOSITION

NEW SUBSTANCE LIBRARY AND THUS MANUFACTURE SUPRAMOLEKULARE OF COMPLEXES

Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease

ACE INHIBITING ANTI-HYPERTENSIVE AGENTS

Novel dipeptide compounds and uses thereof

Provided herein are novel compounds of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical compositions comprising the same. Also provided are methods of preparing the compounds of Formula I, or pharmaceutically acceptable salt thereof. Further provided are methods of using the novel compounds of Formula I, or a pharmaceutically acceptable salt thereof, for example, for inhibiting thrombin and/or for the use in the prevention and/or treatment of thrombin-mediated and thrombin-related diseases.

Novel peptoid polymers and methods of use

The present invention provides peptoid polymers and salts thereof that comprise hydrophobic and polar peptoid monomers and are capable of reducing or inhibiting the formation of ice crystals at sub 0° C temperatures. Also provided are peptoid-peptide hybrids and salts thereof comprising the peptoid polymers provided herein. The peptoid polymers, peptoid-peptide hybrids, and salts thereof provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, salts thereof, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

Thiocationic lipids, pharmaceutical compositions and methods of use thereof

Inhibitors of cancer cell, T-cell and keratinocyte proliferation

The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is -NRR, -NRC=ONRR -NRC=SNRR, -NRC=NRNR, heterocycle, - C=ONRR, heterocycle, or aryl; n is O to 8; m is 0, or 1 ; r is 0 to 3; t is O to 3; X is O or N; Z is CH, C=O, C=S or a single bond; Z is CO-R, CS-R, (CH)-R or the side-chain of a naturally occuring amino acid; , Z is CO-R , CS-R or (CH)-R or the side-chain of a naturally occuring amino acid; Z is CO-R, CS-R or (CH)-R or the side-chain of a naturally occuring amino acid; Zis H, alkyl, alkoxy, or cycloalkyl; R, R, R, and R are independently from each other H, OH, SH, NH, CN, NO, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylarnino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.

Peptidyl diacylglycerides

Alanine 2, 3 aminomutases

METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE ENZYMATIC ACTIVITY

Peptidomimetic protease inhibitors

HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Hemiasterlin derivatives and uses thereof

Abstract The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein RI-R 7, XI, X2, R, Q, and n are as defined herein. RfN X N N-R'-'Q (I) C\NRPortbI\DCC\DAH905S5 1 DOC - 13/1/12 ...

PNA synthesis using a base-labile amino protecting group

Synthesis of a serine protease inhibitor

Peptidic detones as interleukin-1beta-converting enzyme inhibitors

Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

Retroviral protease inhibiting compounds

Cascade polymer complexes method of manufacture, and pharmaceutical agents containing them

PEPTIDE PHOSPHONATES

METHOD OF LOWERING BLOOD SUGAR LEVEL IN VERTEBRATES

PSYCHOPHARMACOLOGICALLY ACTIVE PEPTIDES

TRIPEPTIDES

PEPTIDASE INHIBITORS

This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.

PEPTIDES WHICH ARE ACTIVE ON THE CENTRAL NERVOUS SYSTEM AND HAVE AN ACTION ON THE CHOLINERGIC SYSTEM

... - 1 - HOE 84/F 247 of the disclosure: The invention relates to peptides of the formula I R4 - A5 - A6 - R7 (I) in which R4 denotes an acyl group R5 denotes D-Lys or Lys, A6 denotes the radical of phenylalanie, N-methyl-phenylalanine, 4-alkoxyphenylalanine or 1,2,3,4-tetra-hydroisoquinoline-3-carboxylic acid, and R7 denotes a basic radical, processes for their preparation and their use .

METHODS AND COMPOSITIONS FOR PREPARATION OF H-ARG-X-Z-Y-TYR-R

METHODS AND COMPOSITIONS FOR PREPARATION OF H-ARG-X-Z-Y-TYR-R solution phase methods and compositions for preparing H-ARG-X-Z-Y-TYR-R wherein X is LYS and Y is VAL or X and Y are both SAR, Z is ASP or GLU, and R is NH2 or OH. The compositions of this peptide find use in thymic function.

PEPTIDES RENFERMENT UN GROUPE ACIDE (ALPHA)-AMINOBORIQUE

1-PHENYL-2-AMINOETHANOL DERIVATIVES

METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE ENZYMATIC ACTIVITY

The present invention relates to the use of ~tethering~ to identify compounds that modulate enzymatic activity as shown in the figure.

AMINO THIOL PEPTIDES

HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS

The invention relates to marker molecules for identifying physical properties of molecular species separated by the use of electrophoretic systems. The invention further relates to methods for preparing and using marker molecules.

METHODS AND COMPOSITIONS FOR PREPARATION OF THE PENTAPEPTIDE, ALPHA-T-OMEGA-T' -ARG-X-OMEGA-U-Z-Y-TYR-R'

DERIVATIVES OF DOLASTATIN

Novel derivates of dolastatin of formula (1) in which R1, R2, A. B, D, E, F, G, K, X, t, u, v, and w have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.

CYCLIC PEPTIDES

A novel peptide represented by formula (I): Cyclo-(Cys-Val-d-Phe-Pro)2 (I) wherein Cys indicates a cysteine group, Val indicates a valine group, d-Phe indicates a d-phenylalanine group, Pro indicates a proline group, and Cyclo indicates a cyclic form. This peptide is formed by way of active esterification or azidation of an intermediate: Boc-Cys(Acm)-Val-Cys(Acm)-d-Phe-Pro-OME wherein Boc indicates an amino group protected by a tbutyloxycarbonyl group, Acm indicates an SH group protected by an acetamidomethyl group, and OMe indicates a methoxylated carboxyl group.

THERAPEUTIC PEPTIDE DERIVATIVES

Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively enhanced biological activity when compared to the corresponding peptide alone.

INHIBITORS OF FARNESYL PROTEIN TRANSFERASE

Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein: A1 and A2 are each independently H, alkyl, substituted alkyl, phenyl or substituted phenyl Y and Z are each independently -CH2- or -C(O)-; R1 and R2 are each independently H or alkyl; R1 and A1 taken together may be -(CH2)m-R3 is H, alkyl or phenyl; J, K and L are each independently, N, NR4, O, S or CR5 with the provisos that only one of the groups J, K and L can be O or S, one or two of the groups J, K and L may be N or NR4, and at least one of the groups J or L must be N, NR4, O or S to form a fused five-membered heteroring; the bond between J and K or K and L may also form one side of a phenyl ring fused to the fused five-membered heteroring; x is O or NR6; R4 is H, alkyl or phenylalkyl; R5 is H or alkyl; R6 is H, alkyl, phenyl, phenylalkyl, substituted ...

SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS

This invention relates to substituted cyclic carbonyls and derivatives thereof useful as Human Immnunodifiency Virus (HIV) protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating HIV infection.

METHODS OF DETECTING COLLAGEN DEGRADATION IN VIVO

Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. Suitable methods include immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structures of specific peptides having cross-li nks and kits for quantitating these peptides in a body fluid are described.

CINNAMIC ACID DERIVATIVE

The invention provides a cinnamic acid derivative having a novel spacer introduced into cinnamic acid which is photodimerizable, a cinnamic acid-polymer derivative photocurable with high sensitivity and efficiency obtainable by introducing the above cinnamic acid derivative into a host polymer such as a glycosaminoglycan, and a photocrosslinked cinnamic acid-polymer derivative obtainable by exposing the same cinnamic aicd-polymer derivative to ultraviolet light irradiation.

VITRONECTIN RECEPTOR ANTAGONISTS, THEIR PREPARATION AND THEIR USE

Vitronectin receptor antagonists, their preparation and their use The present invention relates to compounds of the formula I A-B-D-E-F-G (I) in which A, B, D, E, F and G have the meanings given in the patent claims, to th eir preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

APPLICATION AND PRODUCTION PROCESS OF A GROUP OF ANTICANCER COMPOUNDS

A group of specific branched-chain fatty acids, with significant anticancer effects on human and animals; methods of making using either chemical synthesis or biosynthesis methods; and methods of treating cancer.

SYNTHETIC ANTIBIOTICS

Compositions of the current invention are directed toward inhibiting the growth of microorganisms, particularly fungi. The compositions consist of chemically-synthesized antibiotics comprising certain amino acids. Methods of identifying particular antibiotic compositions from libraries of such compositions are disclosed. In addition, methods for preventing microbial growth in plants and animals are disclosed. Methods and compositions are also disclosed which relate to synergistic combinations of inhibitory peptides with other antimicrobial compounds.

Verfahren zur Herstellung von N(Im)-Carbobenzoxyhistidinverbindungen

Verfahren zur Herstellung von neuen Polypeptiden mit verschiedenen biologischen Wirkungen

Verfahren zur Herstellung von Estern

Verfahren zur Herstellung von N-(N-Acyl-aminoacyl)-aminoacetonitrilen

PROCEDURE FOR THE PRODUCTION OF NEW PEPTIDDERIVATE.